Table 5.
Area under the curve comparisons for plasma and CSF biomarkers for the identification of amyloid-PET positivity in the TRIAD cohort
| Immunoassay | MS | 95% CI of difference | p-value | |
|---|---|---|---|---|
| Amyloid-PET positivity in whole cohortsss | ||||
| p-tau181 | 88% (81–95%) | 80% (73–87%) | 1 – 17% | 0.03 |
| p-tau217 | 94% (90–98%) | 92% (87–97%) | -3 – 3% | 0.95 |
| p-tau231 | 92% (87–96%) | 92% (88–97%) | -4 – 3% | 0.68 |
| Amyloid-PET positivity in CU individuals | ||||
| p-tau181 | 83% (72–94%) | 79% (69–88%) | -9 – 26% | 0.33 |
| p-tau217 | 90% (80–98%) | 90% (79–98%) | -6 – 6% | 0.99 |
| p-tau231 | 88% (78–97%) | 91% (81–99%) | -9 – 2% | 0.25 |
| Amyloid-PET positivity in CI individuals | ||||
| p-tau181 | 87% (77–96%) | 74% (65–84%) | -1 – 20% | 0.08 |
| p-tau217 | 91% (81–98%) | 86% (77–95%) | -1 – 11% | 0.09 |
| p-tau231 | 87% (78–97%) | 86% (76–96%) | -5 – 8% | 0.71 |
AUCs were compared using DeLong’s test. Values in parentheses represent 95% Confidence intervals